摘要
目的研究对经皮冠状动脉介入治疗术(PCI)后心肌梗死合并糖尿病患者给予替罗非班和利拉鲁肽联合治疗的临床疗效。方法2021年1—12月于联勤保障部队第九〇〇医院经PCI后心肌梗死合并糖尿病患者随机抽取74例作为研究对象,分为两组,对照组采取二甲双胍+替罗非班+阿司匹林,观察组给予利拉鲁肽+替罗非班+阿司匹林,对比两组治疗效果。结果观察组治疗有效率(94.59%)较对照组(78.38%)明显提高,差异有统计学意义(P<0.05)。观察组FPG(8.25±3.30)mmol/L、2 hPG(7.42±4.38)mmol/L、HbAlc(8.26±4.27)%显著优于对照组的(9.68±2.75)mmol/L、(8.34±5.35)mmol/L、(9.74±3.50)%,差异有统计学意义(P<0.05)。观察组不良反应发生率8.11%和对照组8.11%对比,差异无统计学意义(P>0.05)。结论对于接受PCI介入治疗后发生心肌梗死合并糖尿病患者采取替罗非班+利拉鲁肽能够稳定血糖水平,有利于提高临床疗效,且不会增加不良反应事件,具有较高应用价值。
Objective To investigate the clinical efficacy of tirofiban combined with liraglutide in patients with myocardial infarction and diabetes after percutaneous coronary intervention(PCI).Methods From January to December 2021,74 patients with myocardial infarction and diabetes after PCI were randomly selected from the 900th Hospital of the Joint Support Force as the study subjects and divided into two groups.The control group received metformin+tirofiban+aspirin,and the observation group received liraglutide+tirofiban+aspirin.The therapeutic effect of the two groups was compared.Results The effective rate in the observation group(94.59%)was significantly higher than that in the control group(78.38%),the difference was statistically significant(P<0.05).FPG(8.25±3.30)mmol/L,2 hPG(7.42±4.38)mmol/L,HbAlc(8.26±4.27)%in the observation group were significantly better than the control group[FPG(9.68±2.75)mmol/L,2 hPG(8.34±5.35)mmol/L,HbAlc(9.74±3.50)%],the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 8.11%and there was no statistically significant difference compared to 8.11%in the control group(P>0.05).Conclusion Tirofiban+liraglutide can stabilize blood glucose level in patients with myocardial infarction complicated with diabetes after PCI intervention,which is conducive to improving clinical efficacy and does not increase adverse events,so it has high application value.
作者
张永强
ZHANG Yongqiang(Department of Cardiovascular Medicine,Cangshan Hospital of the 900th Hospital of Joint Logistic Support Force,Fu-zhou,Fujian Province,350002 China)
出处
《糖尿病新世界》
2023年第4期93-96,共4页
Diabetes New World Magazine
关键词
经皮冠状动脉介入治疗
心肌梗死
糖尿病
替罗非班
利拉鲁肽
Percutaneous coronary intervention
Myocardial infarction
Diabetes mellitus
Tirofiban
Liraglutide
